Drug

rhPTX-2

Status:
Phase 3
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Industry

Drug Details

rhPTX-2 (formerly PRM-151) is recombinant human pentraxin-2 , a novel antifibrotic agent with activity on monocyte differentiation, being studied for the treatment of IPF.

Study Purpose

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; formerly PRM-151) compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial